These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26704964)

  • 21. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
    Troche CJ; Tacke J; Hinzpeter B; Danner M; Lauterbach KW
    Eur Heart J; 1998 Apr; 19 Suppl C():C59-65. PubMed ID: 9597427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.
    Chen J; Shi C; Mahoney EM; Dunn ES; Rinfret S; Caro JJ; O'Brien J; El-Hadi W; Bhatt DL; Topol EJ; Cohen DJ
    Can J Cardiol; 2011; 27(2):222-31. PubMed ID: 21459271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
    Ademi Z; Reid CM; Hollingsworth B; Stoelwinder J; Steg PG; Bhatt DL; Vale M; Liew D;
    Clin Ther; 2011 Oct; 33(10):1456-65. PubMed ID: 21982384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global economic and health benefits of tobacco control: part 1.
    Wipfli H; Samet JM
    Clin Pharmacol Ther; 2009 Sep; 86(3):263-71. PubMed ID: 19536067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The burden and costs of chronic diseases in low-income and middle-income countries.
    Abegunde DO; Mathers CD; Adam T; Ortegon M; Strong K
    Lancet; 2007 Dec; 370(9603):1929-38. PubMed ID: 18063029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobacco use and the cardiovascular disease epidemic in developing countries: global crises and opportunity in the making.
    Asma S; Mensah GA; Warren CW; Henson R
    Ethn Dis; 2003; 13(2 Suppl 2):S81-7. PubMed ID: 13677419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling the implications of regular increases in tobacco taxation in the tobacco endgame.
    Cobiac LJ; Ikeda T; Nghiem N; Blakely T; Wilson N
    Tob Control; 2015 Jun; 24(e2):e154-60. PubMed ID: 25145342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals.
    Ezzati M; Riboli E
    Science; 2012 Sep; 337(6101):1482-7. PubMed ID: 22997325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroke and cardiovascular diseases: the need for a global approach for prevention and drug development.
    Hilbrich L; Truelsen T; Yusuf S
    Int J Stroke; 2007 May; 2(2):104-8. PubMed ID: 18705961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications.
    Gersh BJ; Sliwa K; Mayosi BM; Yusuf S
    Eur Heart J; 2010 Mar; 31(6):642-8. PubMed ID: 20176800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cigarette tax increase and media campaign cost of reducing smoking-related deaths.
    Fishman PA; Ebel BE; Garrison MM; Christakis DA; Wiehe SE; Rivara FP
    Am J Prev Med; 2005 Jul; 29(1):19-26. PubMed ID: 15958247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can we prevent cardiovascular diseases in low- and middle-income countries?
    Lenfant C
    Bull World Health Organ; 2001; 79(10):980-2; discussion 983-7. PubMed ID: 11693981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology and public health policy of tobacco use and cardiovascular disorders in low- and middle-income countries.
    Saleheen D; Zhao W; Rasheed A
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1811-9. PubMed ID: 25035346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic factors in formulating a national policy on the prevention by drugs of cardiovascular disease.
    Malcolm L
    N Z Med J; 1990 Aug; 103(896):402-4. PubMed ID: 2117264
    [No Abstract]   [Full Text] [Related]  

  • 40. Scaling up interventions for chronic disease prevention: the evidence.
    Gaziano TA; Galea G; Reddy KS
    Lancet; 2007 Dec; 370(9603):1939-46. PubMed ID: 18063028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.